Abstract
Objectives: The aim of this study was to investigate the relationship between BRCA1 and mitotic arrest deficiency protein 2 (MAD2) protein expression, as determined by immunohistochemistry, and clinical outcomes in epithelial ovarian carcinoma (EOC). Methods: A tissue microarray consisting of 94 formalin-fixed paraffin-embedded EOC with fully matched clinicopathological data were immunohistochemically stained with anti-BRCA1 and anti-MAD2 antibodies. The cores were scored in a semiquantitative manner evaluating nuclear staining intensity and extent. Coexpression of BRCA1 and MAD2 was evaluated, and patient survival analyses were undertaken. Results: Coexpression of BRCA1 and MAD2 was assessed in 94 EOC samples, and survival analysis was performed on 65 high-grade serous carcinomas (HGSCs). There was a significant positive correlation between BRCA1 and MAD2 expression in this patient cohort (P < 0.0001). Both low BRCA1 and low MAD2 are independently associated with overall survival because of HGSC. Low coexpression of BRCA1 and MAD2 was also significantly associated with overall survival and was driven by BRCA1 expression. Conclusion: BRCA1 and MAD2 expressions are strongly correlated in EOC, but BRCA1 expression remains the stronger prognostic factor in HGSC.
| Original language | English |
|---|---|
| Pages (from-to) | 472-478 |
| Journal | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society |
| Volume | 28 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 01 Mar 2018 |
Fingerprint
Keywords
- BRCA1
- Immunohistochemistry
- MAD2
- Prognosis
- Serous ovarian carcinomas
Cite this
}
BRCA1 and MAD2 are Co-expressed and are Prognostic Indicators in Tubo-ovarian High-grade Serous Carcinoma. / Byrne, Tara; Nelson, Laura; Beirne, James; Sharpe, Daniel; Quinn, Jennifer E.; Glenn McCluggage, W.; Robson, Tracy; Furlong, Fiona.
In: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 28, No. 3, 01.03.2018, p. 472-478.Research output: Contribution to journal › Article
TY - JOUR
T1 - BRCA1 and MAD2 are Co-expressed and are Prognostic Indicators in Tubo-ovarian High-grade Serous Carcinoma
AU - Byrne, Tara
AU - Nelson, Laura
AU - Beirne, James
AU - Sharpe, Daniel
AU - Quinn, Jennifer E.
AU - Glenn McCluggage, W.
AU - Robson, Tracy
AU - Furlong, Fiona
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Objectives: The aim of this study was to investigate the relationship between BRCA1 and mitotic arrest deficiency protein 2 (MAD2) protein expression, as determined by immunohistochemistry, and clinical outcomes in epithelial ovarian carcinoma (EOC). Methods: A tissue microarray consisting of 94 formalin-fixed paraffin-embedded EOC with fully matched clinicopathological data were immunohistochemically stained with anti-BRCA1 and anti-MAD2 antibodies. The cores were scored in a semiquantitative manner evaluating nuclear staining intensity and extent. Coexpression of BRCA1 and MAD2 was evaluated, and patient survival analyses were undertaken. Results: Coexpression of BRCA1 and MAD2 was assessed in 94 EOC samples, and survival analysis was performed on 65 high-grade serous carcinomas (HGSCs). There was a significant positive correlation between BRCA1 and MAD2 expression in this patient cohort (P < 0.0001). Both low BRCA1 and low MAD2 are independently associated with overall survival because of HGSC. Low coexpression of BRCA1 and MAD2 was also significantly associated with overall survival and was driven by BRCA1 expression. Conclusion: BRCA1 and MAD2 expressions are strongly correlated in EOC, but BRCA1 expression remains the stronger prognostic factor in HGSC.
AB - Objectives: The aim of this study was to investigate the relationship between BRCA1 and mitotic arrest deficiency protein 2 (MAD2) protein expression, as determined by immunohistochemistry, and clinical outcomes in epithelial ovarian carcinoma (EOC). Methods: A tissue microarray consisting of 94 formalin-fixed paraffin-embedded EOC with fully matched clinicopathological data were immunohistochemically stained with anti-BRCA1 and anti-MAD2 antibodies. The cores were scored in a semiquantitative manner evaluating nuclear staining intensity and extent. Coexpression of BRCA1 and MAD2 was evaluated, and patient survival analyses were undertaken. Results: Coexpression of BRCA1 and MAD2 was assessed in 94 EOC samples, and survival analysis was performed on 65 high-grade serous carcinomas (HGSCs). There was a significant positive correlation between BRCA1 and MAD2 expression in this patient cohort (P < 0.0001). Both low BRCA1 and low MAD2 are independently associated with overall survival because of HGSC. Low coexpression of BRCA1 and MAD2 was also significantly associated with overall survival and was driven by BRCA1 expression. Conclusion: BRCA1 and MAD2 expressions are strongly correlated in EOC, but BRCA1 expression remains the stronger prognostic factor in HGSC.
KW - BRCA1
KW - Immunohistochemistry
KW - MAD2
KW - Prognosis
KW - Serous ovarian carcinomas
U2 - 10.1097/IGC.0000000000001214
DO - 10.1097/IGC.0000000000001214
M3 - Article
VL - 28
SP - 472
EP - 478
JO - International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
JF - International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
SN - 1525-1438
IS - 3
ER -